Molecule News and Research

RSS

PolyMedix's PMX-60056 Phase 1B/2 dose-ranging clinical study for heparin reversal meets study endpoints

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a Phase 1B/2 dose-ranging clinical study with PMX-60056, a synthetic small-molecule designed to reverse heparin and low molecular weight heparin anticoagulants.

11 Aug 2010

NKTreg white blood cells migrate into liver, suppress immune responses: Research

After a transplant - and to assure that the new organ is not rejected - patients are put on life-long therapy to suppress their immune system, which, nevertheless, needs to be left intact enough to be able to defend the body against all kinds of disease. A tricky balance as the many rejected organs attest. But a discovery by Maria Monteiro and Luis Graça, two Portuguese scientists, could change all this, at least for the liver.

11 Aug 2010

Dr. Hastings receives grant for Spinal Muscular Atrophy research

Michelle Hastings, PhD, Assistant Professor in the Department of Cell Biology and Anatomy, in the Chicago Medical School of Rosalind Franklin University of Medicine and Science, has been awarded a five-year $1.68 million grant from the National Institutes of Health to support her research aimed at investigating treatments for the fatal children's disease, Spinal Muscular Atrophy (SMA).

11 Aug 2010

Ancient immunoglobulin study explains evolution of human intestinal immune responses

A study at the University of Pennsylvania School of Veterinary Medicine has identified the function of one of the earliest antibodies in the animal kingdom, an ancient immunoglobulin that helps explain the evolution of human intestinal immune responses. It was discovered to play a predominant role in the guts of fish and paves the way for a better understanding of human gut immunity as well as for safer, healthier approaches to keeping fish from pathogen infections. The findings appear in the online version of Nature Immunology and will be featured on the cover of the September issue.

11 Aug 2010

TetraLogic raises $32 million in Series C financing to advance clinical development of TL32711 cancer drug

TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule drugs to treat cancer, today announced it has completed a $32 million Series C financing with new investor Clarus Ventures leading the round.

11 Aug 2010

ACD launches RNAscope Formalin-Fixed, Paraffin-Embedded Assay Kit

Advanced Cell Diagnostics, Inc., announces the launch and immediate availability of RNAscope™ FFPE Assay Kit, a line of RUO products designed to detect RNA biomarkers in routine Formalin-Fixed, Paraffin-Embedded tissue specimens with single molecule sensitivity.

From Advanced Cell Diagnostics 11 Aug 2010

FDA grants Orphan Drug Designation to YM BioSciences' JAK1/2 inhibitor

YM BioSciences Inc., announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration has granted Orphan Drug Designation to the Company's highly-selective JAK1/2 inhibitor, CYT387, for the treatment of myelofibrosis, a chronic debilitating unmet medical need, in which a patient's bone marrow is replaced by scar tissue, and for which treatment options are limited or unsatisfactory.

10 Aug 2010

Epitherix identifies potent and selective multiple chemical scaffolds against colorectal carcinoma

Epitherix, LLC, a privately held company focused on the discovery and development of novel Wnt pathway small molecule inhibitors for epithelial and leukemic cancers, today announced that it has identified multiple chemical scaffolds that are potent and selective against colorectal carcinoma. "We're very encouraged by our in vitro and in vivo data, especially considering the difficulty in drugging this pathway to date," said Dr. Osman Kibar, CEO of Epitherix.

10 Aug 2010

Synta second-quarter net loss increases to $9.1 million

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results for the quarter ended June 30, 2010.

10 Aug 2010

Array BioPharma fiscal 2010 revenue increases to $53.9 million

Array BioPharma Inc. today reported financial results for the fourth quarter and full year of fiscal 2010.

10 Aug 2010

Curis announces preliminary results of GDC-0449 Phase II clinical trial in advanced ovarian cancer

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that it has received preliminary results from a Phase II clinical trial of GDC-0449 from Roche and Genentech, Curis' collaborator and a member of the Roche Group.

9 Aug 2010

Intellect Neurosciences receives Notice of Allowance for new OXIGON patent in Canada

Intellect Neurosciences, Inc announced that it has received a Notice of Allowance from the Canadian Patent and Trademark Office for a new patent related to OX1 (OXIGON™), the Company's clinical-stage drug candidate that has disease-modifying potential for Alzheimer's and other neurodegenerative disorders. OX1 is an orally-administered, brain-penetrating, naturally-occurring, copper-binding small molecule targeting multiple mechanisms that contribute significantly to the underlying pathology of Alzheimer's disease.

9 Aug 2010

Dr Reddy’s launches first generic darbepoetin alfa

Dr. Reddy's Laboratories Ltd. announced today the launch of Cresp® - the first generic darbepoetin alfa in the world, and the only darbepoetin alfa in India. Cresp® has been approved in India for the treatment of anemia due to chronic kidney disease and anemia due to chemotherapy.

9 Aug 2010

Apte wins Elkeles Prize for outstanding scientist in field of medicine

Ben-Gurion University of the Negev (BGU) Professor Ron N. Apte has been awarded the 2010 Samuel and Paula Elkeles Prize for Outstanding Scientist in the Field of Medicine.

9 Aug 2010

Ardea Biosciences second-quarter total revenues decline to $3.5 million

Ardea Biosciences, Inc., a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, reported recent accomplishments and financial results for the second quarter and six months ended June 30, 2010.

7 Aug 2010

Study identifies options for restoring knee cartilage lubrication to prevent OA

An injury to the anterior cruciate ligament is fairly common, especially among young athletes. While it can often be corrected through surgery, the injury can lead to increased risk of developing degenerative joint diseases, including osteoarthritis. The problem is that fluid in the knee joint, which lubricates the cartilage, is impacted by the trauma of the injury and begins to deteriorate.

6 Aug 2010

WaferGen launches SmartChip System for discovery, validation of biomarkers

WaferGen Biosystems, Inc., a leading developer of state-of-the-art genomic analysis systems, today announced it has launched the breakthrough WaferGen SmartChip Real-Time PCR System, the next-generation Real-Time PCR system for discovery and validation of biomarkers, or gene expression patterns, on a single platform. The SmartChip System is designed to provide accurate, highly sensitive and high-throughput gene expression profiling capabilities to researchers, clinicians and pharmaceutical companies.

6 Aug 2010

Ligand second-quarter net loss reduces to $0.3 million

Ligand Pharmaceuticals Incorporated today announced financial results for the three and six months ended June 30, 2010 and provided an update on key programs.

5 Aug 2010

YM concludes dose-escalation in CYT387 Phase I/II clinical trial for myelofibrosis

YM BioSciences Inc., announced the conclusion of dose-escalation in the Phase I portion of its Phase I/II clinical trial of CYT387 at Mayo Clinic in patients with myelofibrosis. In total, 21 patients were treated in Phase I, with no voluntary withdrawals reported. CYT387 has shown significant activity in reducing spleen size and controlling constitutional symptoms in these patients.

5 Aug 2010

ARIAD reports $159.3 million second-quarter net income

ARIAD Pharmaceuticals, Inc. today reported financial results for the second quarter and six months ended June 30, 2010 and provided an update on corporate developments.

5 Aug 2010

Molecule News and Research

PolyMedix's PMX-60056 Phase 1B/2 dose-ranging clinical study for heparin reversal meets study endpoints

NKTreg white blood cells migrate into liver, suppress immune responses: Research

Dr. Hastings receives grant for Spinal Muscular Atrophy research

Ancient immunoglobulin study explains evolution of human intestinal immune responses

TetraLogic raises $32 million in Series C financing to advance clinical development of TL32711 cancer drug

ACD launches RNAscope Formalin-Fixed, Paraffin-Embedded Assay Kit

FDA grants Orphan Drug Designation to YM BioSciences' JAK1/2 inhibitor

Epitherix identifies potent and selective multiple chemical scaffolds against colorectal carcinoma

Synta second-quarter net loss increases to $9.1 million

Array BioPharma fiscal 2010 revenue increases to $53.9 million

Curis announces preliminary results of GDC-0449 Phase II clinical trial in advanced ovarian cancer

Intellect Neurosciences receives Notice of Allowance for new OXIGON patent in Canada

Dr Reddy’s launches first generic darbepoetin alfa

Apte wins Elkeles Prize for outstanding scientist in field of medicine

Ardea Biosciences second-quarter total revenues decline to $3.5 million

Study identifies options for restoring knee cartilage lubrication to prevent OA

WaferGen launches SmartChip System for discovery, validation of biomarkers

Ligand second-quarter net loss reduces to $0.3 million

YM concludes dose-escalation in CYT387 Phase I/II clinical trial for myelofibrosis

ARIAD reports $159.3 million second-quarter net income

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News